

CDU Curriculum: Cellulitis

By: Nick Rankin, MD

Elizabeth Lee, MD

Objectives

- Define cellulitis
- Define how to identify
- Define when to hospitalize
- Explain role of CDU
- Touch on special Types

Cellulitis Defined

- Skin Infection as a result of bacteria breaching the skin barrier replicating in the tissue
- Presents with Pain Erythema Edema


Diagnosis

- Based on clinical presentation
- Biopsy not generally useful
- If suspect more systemic infection blood cultures
- Inspect for source of skin barrier breakdowns IE spider bite
- X-ray is suspect underlying foreign body or osteomyelitis
- Ultrasound for abscess "cobblestoning"



Pathology

- Bacterial Pathogens
- Most commonly Staph and Strep Including MRSA
- Much less likely gram negative pathogens
- Determined by risk factors



MICROBIOLOGY

SSTI Type	Common organisms					
Non-purulent	 Streptococcus pyogenes (Group A strep) - most common Streptococcus agalactiae (Group B strep or GBS) Other beta-hemolytic Streptococci (Groups C, G) Staphylococcus aureus (mostly MSSA) 					
Purulent	Staphylococcus aureus (MSSA/MRSA) – most common Beta-hemolytic Streptococci					
Complicated SSTI and Necrotizing fasciitis	 Streptococcus pyogenes Staphylococcus aureus Gram negative rods Clostridium species May be polymicrobial including mixed aerobic and anaerobic flora 					

Treatment Recommendations

- Tailor antibiotics by regional antibiogram and symptoms
- MRSA coverage if
 - Purulent drainage
 - Penetrating trauma
 - Known MRSA colonization
 - IV drug use
 - SIRS/Sepsis
- Usually 5-day treatment duration

	# of patients	Aminoglycosides			B-Lactams			Cephalosporins			Quinolones		Others			
Gram (-)		Amikacin	Genta micin	Tobramycin	Ampicillin	Impipnem	Pipercillinp Tazobactam	Cefzolin	Cefexitin	Ceffria xo ne	Ceftazidime	Ciprofloxacin	Nitrofurantion	TMP/SMX		
Echerichia coli	4	100	100	100		100	100				100	75				
Klebsiella sp	13	100	84.6	92.3	38.5	100	92.3	84.6	100	100	100	38.5	92.3		38.5	
Proteus sp	7	71.4	57.1	71.4		85.7	85.7			57.1	57.1		28.6		71.4	
Pseudomonas aeruginosa	13	100	83.3	92.3	91.7		100		81.8	100	100	30.8			69.2	
		P	enicilli	ns		Cephal	osporins	Quino	lones				Others		V.S.	
Gram (-)	# of patients	Penicillins	Ampicillin	Oxacillin	Nafcillin	Cephalothin	Ceffriaxone	Ciproflexacin	Moxifloxucin	Gentamacin	Linezoid	Rifampin	Tetracycline	TMP/SMX	Vancomycin	Nitrofurantion
Staph aureus (all)	8	0		0	0			0	0	87.5	100	100	100	100	100	100
Methicillin Resistant (MRSA)	8	0		0	0				0	87.5	100	100	100	100	100	100
Methicillin Susceptible (MRSA)	0															
Enterococcus sp	4	100	100					50		75			25		100	100

SSTI SEVERITY CLASSIFICATION

Classification	Definition
Mild	Local symptoms only without signs of systemic infection
Moderate	 Local symptoms with signs of systemic infection or SIRS (temperature >100.4 F, HR >90 bpm, RR >20 breaths/min, WBC >12,000 cells/mm³) Rapid progression of erythema without signs of systemic toxicity Local symptoms in close proximity to indwelling device or prosthetic Clinical worsening despite appropriate oral antibiotic treatment ≥ 48 hours
Severe	 Patients with suspected / confirmed necrotizing fasciitis Rapid progression of erythema with signs of systemic toxicity Patients who have clinical worsening despite initial appropriate IV therapy / clinical worsening ≥48 hours Severely immunocompromised patients (hematologic cancer with neutropenia, hematopoietic stem cell transplantation, solid-organ transplant <3 months) Patients with severe sepsis (refer to Sepsis Guidelines)

Treatment Recommendations

Reasons to inpatient admit

- OR debridement/washout
- Sepsis
- Significant involvement of face or genitalia
- Significant comorbidity requiring treatment

	Mild infections with complete I&D may not require antibiotics (see above)	5 days				
Mild	Sulfamethoxazole/trimethoprim 1-2 DS tab po Q12h OR doxycycline 100 mg po Q12h					
Moderate	Vancomycin IV ^b	5 – 7 days (may consider extending treatment if infection has not improved)				
Severe- Purulent refer to table above if any concern for necrotizing fasciitis. Cellulitis	$\label{eq:Vancomycin IV} \mbox{Vancomycin IV}^{b} + \mbox{piperacillin/tazobactam 3.375 g} \\ \mbox{IV q8h} \\ \mbox{OR}$	7 – 14 days based on clinical response				
	Vancomycin IV ^b + cefepime 2 g IV q8h + metronidazole 500 mg IV q8h					
	Non-IgE mediated beta-lactam allergy ^a :					
	Vancomycin IV ^b + cefepime 2 g IV q8h + metronidazole 500 mg IV q8h					
	Severe beta-lactam allergy: Vancomycin IV ^b + astreonam 2 g IV q8h + metronidazole 500 mg IV q8h					
	Moderate Severe- refer to table above if any concern for	require antibiotics (see above) Sulfamethoxazole/trimethoprim 1-2 DS tab po Q12h OR doxycycline 100 mg po Q12h Vancomycin IV ^b Vancomycin IV ^b + piperacillin/tazobactam 3.375 g IV q8h OR Vancomycin IV ^b + cefepime 2 g IV q8h + metronidazole 500 mg IV q8h Non-IgE mediated beta-lactam allergy ^c : Vancomycin IV ^b + cefepime 2 g IV q8h + metronidazole 500 mg IV q8h Severe beta-lactam allergy· Vancomycin IV ^b + attreonam 2 g IV q8h +				

Role of CDU

Inclusion Criteria

 Probability of D/C within 24 Hours >80%

Exclusion Criteria

- Meets Inpatient criteria
- Suspect Necrotizing fasciitis
- SIRS/Sepsis

Cellulitis in CDU

- Review of ED lab work and imaging
- ABX
- Analgesia
- Mark areas of involvement
- Elevate area of involvement
- D/C planing and care coordination
- Don't forget to treat withdrawal



CDU Pathway to Home vs Admit

- Home if
- Stable course
- Clinical improvement
- Tolerating meds
- Follow up arranged

- Admit if
- Requires IV antibiotic > 24 hours
- Developing SIRS/Sepsis
- Hemodynamic instability

Special types of cellulitis-Orbital

- Cellulitis of the periorbital soft tissues and evidence of eye dysfunction from pressure ie proptosis double vision painful EOM ECT
- Evaluation included CT orbit W contrast
- Ocular emergency
- Analogous to compartment syndrome
- IV ABX and optho consult



Special types of cellulitis- Hand

- If involving flexor surface raise level of concern
- Hand surgery consult
- Is a "compartment syndrome" of the flexor tendons within their sheath

